The reported statements, read against the company's own industry.
What stands out
Earnings significantly exceed cash generation
Financials view
Market Capitalization
4.16MGBP
5.62M · vs all stocks (USD)
Updated Jul 28, 2026
Trailing P/E
1.75x
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Revenue (TTM)
8.06MGBP
10.88M · vs all stocks (USD)
Updated Jul 28, 2026
Profit Margin
16.94%
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Beta
1.91x
vs all stocks
Updated Jul 28, 2026
52-Week Change
-53.33%
vs all stocks
Updated Jul 28, 2026
Market Capitalization
4.16MGBP
5.62M · vs all stocks (USD)
Updated Jul 28, 2026
Enterprise Value
807.14KGBP
1.09M · vs all stocks (USD)
Updated Jul 28, 2026
Trailing P/E
1.75x
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Price to Sales (TTM)
0.5167x
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Price to Book (MRQ)
0.3804x
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Enterprise to Revenue
0.1000x
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Enterprise to EBITDA
-2.48x
vs Medical Instruments & Supplies peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 2.2×.Updated Jul 28, 2026
Profit Margin
16.94%
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Operating Margin
-7.69%
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Return on Assets (TTM)
-2.58%
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Return on Equity (TTM)
13.26%
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Revenue (TTM)
8.06MGBP
10.88M · vs all stocks (USD)
Updated Jul 28, 2026
Revenue per Share (TTM)
0.0340GBPUpdated Jul 28, 2026
Quarterly Revenue Growth
-6.60%
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Gross Profit (TTM)
5.35MGBP
7.23M · vs all stocks (USD)
Updated Jul 28, 2026
EBITDA (TTM)
367.00KGBP
495.64K · vs all stocks (USD)
Updated Jul 28, 2026
Net Income (TTM)
1.36MGBP
1.84M · vs all stocks (USD)
Updated Jul 28, 2026
Operating Cash Flow (TTM)
-270.00KGBP
-364.64K · vs all stocks (USD)
Updated Jul 28, 2026
Levered Free Cash Flow (TTM)
-49.88KGBP
-67.36K · vs all stocks (USD)
Updated Jul 28, 2026
Trailing Annual Dividend Rate
0.00GBPUpdated Jul 28, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Jul 28, 2026
Payout Ratio
0.00%
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Revenue
8.33MGBPFY2025 · Mar 31, 2025
Cost of Goods Sold
2.89MGBPFY2025 · Mar 31, 2025
Gross Profit
5.44MGBPFY2025 · Mar 31, 2025
Operating Income
-395.00KGBP
-533.46K · vs all stocks (USD)
FY2025 · Mar 31, 2025
Pre-tax Income
1.57MGBPFY2025 · Mar 31, 2025
Income Tax Expense
0.00GBPFY2025 · Mar 31, 2025
Net Income
1.57MGBPFY2025 · Mar 31, 2025
EBIT
1.58MGBPFY2025 · Mar 31, 2025
EBITDA (Income Statement)
367.00KGBPFY2025 · Mar 31, 2025
Selling, General & Administrative
6.12MGBPFY2025 · Mar 31, 2025
Non-operating Interest Income
147.00KGBPFY2025 · Mar 31, 2025
Non-operating Interest Expense
17.00KGBPFY2025 · Mar 31, 2025
EPS (Basic)
0.0070GBPFY2025 · Mar 31, 2025
EPS (Diluted)
0.0070GBPFY2025 · Mar 31, 2025
Basic Shares Outstanding
237.95MSharesFY2025 · Mar 31, 2025
Diluted Shares Outstanding
237.95MSharesFY2025 · Mar 31, 2025
Net Income from Continuing Operations
1.57MGBPFY2025 · Mar 31, 2025
Preferred Stock Dividends
0.00GBPFY2025 · Mar 31, 2025
Operating Cash Flow
-1.24MGBPFY2025 · Mar 31, 2025
Free Cash Flow
-1.47MGBPFY2025 · Mar 31, 2025
Cash & Cash Equivalents (End of Period)
4.87MGBPFY2025 · Mar 31, 2025
Starting Profit (CF Statement)
1.57MGBPFY2025 · Mar 31, 2025
Stock-based Compensation
186.00KGBPFY2025 · Mar 31, 2025
Other Non-cash Items
-130.00KGBPFY2025 · Mar 31, 2025
Change in Accounts Receivable (CF)
-141.00KGBPFY2025 · Mar 31, 2025
Change in Other Assets/Liabilities
-2.72MGBPFY2025 · Mar 31, 2025
Capital Expenditures
-225.00KGBPFY2025 · Mar 31, 2025
Net Intangibles (CF)
-157.00KGBPFY2025 · Mar 31, 2025
Net Investing Cash Flow
-225.00KGBPFY2025 · Mar 31, 2025
Long-term Debt Payments
-140.00KGBPFY2025 · Mar 31, 2025
Net Financing Cash Flow
-140.00KGBPFY2025 · Mar 31, 2025
Shares Outstanding
237.95MSharesUpdated Jul 28, 2026
Float Shares
187.43MSharesUpdated Jul 28, 2026
% Held by Insiders
25.47%
vs all stocks
Updated Jul 28, 2026
% Held by Institutions
4.60%
vs all stocks
Updated Jul 28, 2026
Total Cash (MRQ)
3.59MGBP
4.85M · vs all stocks (USD)
Updated Jul 28, 2026
Total Cash per Share (MRQ)
0.0150GBPUpdated Jul 28, 2026
Total Debt (MRQ)
237.00KGBP
320.08K · vs all stocks (USD)
Updated Jul 28, 2026
Total Debt to Equity (MRQ)
0.0214x
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Current Ratio (MRQ)
4.25x
vs Medical Instruments & Supplies peers
Updated Jul 28, 2026
Book Value per Share (MRQ)
0.0460GBPUpdated Jul 28, 2026
Total Assets
13.65MGBP
18.43M · vs all stocks (USD)
FY2025 · Mar 31, 2025
Total Current Assets
7.66MGBPFY2025 · Mar 31, 2025
Total Liabilities
2.24MGBPFY2025 · Mar 31, 2025
Total Non-current Assets
5.99MGBPFY2025 · Mar 31, 2025
Total Non-current Liabilities
126.00KGBPFY2025 · Mar 31, 2025
Total Current Liabilities
2.12MGBPFY2025 · Mar 31, 2025
Cash & Cash Equivalents
4.87MGBPFY2025 · Mar 31, 2025
Accounts Receivable
1.46MGBPFY2025 · Mar 31, 2025
Inventory
829.00KGBPFY2025 · Mar 31, 2025
Accounts Payable
766.00KGBPFY2025 · Mar 31, 2025
Short-term Debt
223.00KGBPFY2025 · Mar 31, 2025
Long-term Debt
126.00KGBPFY2025 · Mar 31, 2025
Common Stock (Book)
10.26MGBPFY2025 · Mar 31, 2025
Retained Earnings
-23.83MGBPFY2025 · Mar 31, 2025
Total Shareholders' Equity
11.41MGBP
15.41M · vs all stocks (USD)
FY2025 · Mar 31, 2025
52-Week Low
1.60GBXUpdated Jul 28, 2026
52-Week High
3.75GBXUpdated Jul 28, 2026
52-Week Change
-53.33%
vs all stocks
Updated Jul 28, 2026
Beta
1.91x
vs all stocks
Updated Jul 28, 2026
50-Day MA
1.81GBXUpdated Jul 28, 2026
200-Day MA
2.02GBXUpdated Jul 28, 2026
Avg 10-Day Volume
119.66KSharesUpdated Jul 28, 2026
Avg 30-Day Volume
128.71KSharesUpdated Jul 28, 2026
Diluted EPS (TTM)
0.0100GBPUpdated Jul 28, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 1.75×, lower than 95% of its Medical Instruments & Supplies peers (median 30.34×)Notable